Polymer-based immunotherapies enhance tumor targeting and immune activation
Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less…
Browsing Tag